OpenLB
Open Library of Bioscience
Advanced Search
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
02 14, 2022;194 (6): E218.

Nirmatrelvir-ritonavir for COVID-19.

Emily G McDonald, Todd C Lee
Author Information
  1. Emily G McDonald: Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que. emily.mcdonald@mcgill.ca.
  2. Todd C Lee: Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que.
PMID: 35115376 DOI: 10.1503/cmaj.220081

Abstract

No abstract text available.

References

  1. Open Forum Infect Dis. 2022 Jan 19;9(3):ofac008 [PMID: 35165657]

MeSH Term

Administration, Oral
Cytochrome P-450 CYP3A Inhibitors
Drug Combinations
Drug Interactions
Humans
Lactams
Leucine
Nitriles
Proline
Ritonavir
SARS-CoV-2
Viral Protease Inhibitors
COVID-19 Drug Treatment

Chemicals

Cytochrome P-450 CYP3A Inhibitors
Drug Combinations
Lactams
Nitriles
Viral Protease Inhibitors
nirmatrelvir
Proline
Leucine
Ritonavir
Journal Article Research Support, Non-U.S. Gov't Comment
Article has an altmetric score of 39

Word Cloud

Created with Highcharts 10.0.0Nirmatrelvir-ritonavirCOVID-19

Similar Articles

Cited By